<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582007</url>
  </required_header>
  <id_info>
    <org_study_id>POL7080-010</org_study_id>
    <nct_id>NCT03582007</nct_id>
  </id_info>
  <brief_title>Pivotal Study in Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas</brief_title>
  <acronym>PRISM-UDR</acronym>
  <official_title>A Multicenter, Open Label, Sponsor Blinded, Randomized, Active Controlled, Parallel Group, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of Murepavadin Given With Ertapenem Versus an Anti-pseudomonal-β-lactam-based Antibiotic in Adult Subjects With Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polyphor Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polyphor Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled,
      parallel group to investigate the efficacy, safety and tolerability of intravenous
      murepavadin given with ertapenem versus an anti-pseudomonal β-lactam based antibiotic in the
      treatment of nosocomial pneumonia in adult subjects
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety data review
  </why_stopped>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Actual">July 17, 2019</completion_date>
  <primary_completion_date type="Actual">July 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Sponsor blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality rates</measure>
    <time_frame>28 days after start of study treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Murepavadin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Murepavadin + ertapenem</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti-pseudomonal antibiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One anti-pseudomonal-β-lactam-based antibiotic (either meropenem or piperacillin-tazobactam)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Murepavadin</intervention_name>
    <description>Murepavadin + ertapenem</description>
    <arm_group_label>Murepavadin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>One anti-pseudomonal antibiotic</intervention_name>
    <description>Either meropenem or piperacillin-tazobactam</description>
    <arm_group_label>Anti-pseudomonal antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subject has received mechanical ventilation for at least 48h at the time of the
             randomisation OR at least 2 of the following signs or symptoms presenting within 24
             hours prior to randomization: New onset of cough or worsening of baseline cough and/or
             dyspnea, tachypnea and/or hypoxemia and/or new onset of sputum or suctioned
             respiratory secretion characterized by purulent appearance indicative of bacterial
             infection or a worsening in character of purulent appearance

          -  Acute Physiology and Chronic Health Evaluation (APACHE) of 8 to 25, inclusive, within
             24h prior to randomization

          -  Presence of new or progressive infiltrate on chest X-ray

          -  Presence of clinical criteria consistent with Pneumonia

          -  Strong clinical suspicion of pneumonia due to P. aeruginosa

        Key Exclusion Criteria:

          -  Known or suspected community-acquired bacterial pneumonia or viral, fungal, or
             parasitic pneumonia

          -  known hypersensitivity to any component of ertapenem, meropenem or to other drugs in
             the same class or demonstrated anaphylactic reactions to beta-lactams or a history of
             allergic reactions to any of the penicillins, cephalosporins, or β-lactamase
             inhibitors

          -  Severe liver or renal impairment

          -  Expected survival &lt; 72 hours

          -  Evidence from an available surveillance culture of co infection with ertapenem ,
             meropenem or piperacillin tazobactam resistant Gram negative pathogen(s)

          -  Women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Břeclav</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Kolín</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>August 23, 2019</last_update_submitted>
  <last_update_submitted_qc>August 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Murepavadin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

